With $30M Investment, Regenacy Plans Phase 2 Trial Testing Ricolinostat for CMT Type 2
Financing totaling $30 million will help Regenacy advance ricolinostat into Phase 2 studies in CMT type 2 and other peripheral neuropathies.
0 Comments